Skip to content
Screener

CorMedix CRMD Q1 2025 earnings

Reported May 6, 2025 · Before market open

Revenue$39.1MBeat by $9.2M
EPS$0.30Beat by $0.05
Revenue estimate$29.9M
EPS estimate$0.25

Next report

Nov 11, 2026 (in 2 months)
Revenue estimate$53.3M
EPS estimate-$0.10

Financials

Q1 2025

Income statement

See full
Revenue$39.1M—
Gross profit$37.5M+4,686%
Operating income$20.1M+220%
Net income$20.6M+243%
EPS (diluted)$0.30+220%

Balance sheet

See full
Cash & equivalents$66.4M+87.8%
Total debt$476.0K-24.7%
Total equity$114.9M+98.0%
Total assets$149.6M+120%

Cash flow

See full
Operating cash flow$19.7M+214%
CapEx$10.0K-83.7%
Free cash flow$19.7M+214%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$401.52M+72.2%
Enterprise value$335.6M+69.2%
P/S4.9×—

Profitability

See full
Gross margin95.4%—
FCF margin-16.5%—

Returns & leverage

See full
Debt / equity0×0.0×
Current ratio4.2×-2.4×

Segments

By product

See full
DefenCath$39.1M+260%
Contract revenue-—
Melinta Portfolio-—

FAQ

When did CorMedix report Q1 2025 earnings?
CorMedix (CRMD) reported Q1 2025 earnings on May 6, 2025 before market open.
What were CorMedix's Q1 2025 revenue and EPS?
CorMedix reported revenue of $39.1M and eps of $0.30 for Q1 2025.
Did CorMedix beat estimates in Q1 2025?
Revenue beat the consensus estimate of $29.9M by $9.2M. EPS beat the consensus estimate of $0.25 by $0.05.
Where can I find CorMedix's Q1 2025 SEC filings?
You can read the 8-K earnings release (0001213900-25-039903) and the 10-Q periodic report (0001213900-25-039908) directly on SEC EDGAR. The filing index links above go to sec.gov.